In 2024, the U.S. Drug Enforcement Administration (DEA) indicated that they intend to reclassify cannabis as being a Timetable III drug. This rescheduling will acknowledge that cannabis has legitimate clinical reasons and might help open up the doorway to study on other probable treatment method